"Amarin Corporation Plc - Agreement also provides for HLS to pay Amarin tiered double digit royalties on net sales of Vascepa in Canada"
In addition
"Amarin Corporation Plc says terms of agreement include up-front and milestone payments to Amarin of up to U.S. $65.0 million" (not bad for just Canada)
"Amarin Corporation Plc says HLS will be responsible for regulatory and commercialization activities and associated costs"
I haven't put a pencil to the HLS royalty calculations yet, but I believe "The norm" for these things is a peak of 16%. We'll get there in Canada and ROW eventually.